Open AccessManagement of Chronic Rhinosinusitis with Nasal Polyposis in the Era of Biologics
Author(s) -
Justin C. Morse,
Craig Miller,
Brent A. Senior
Publication year - 2021
Publication title -
journal of asthma and allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.162
H-Index - 30
ISSN - 1178-6965
DOI - 10.2147/jaa.s258438
Subject(s) - medicine , dupilumab , omalizumab , chronic rhinosinusitis , intensive care medicine , nasal polyps , psychological intervention , clinical trial , biologic agents , atopic dermatitis , dermatology , immunology , disease , immunoglobulin e , psychiatry , antibody
Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a phenotypic designation of the broader condition of chronic rhinosinusitis. The advent of targeted biologics has shown promise in targeting different aspects of the inflammatory pathway, yet there remains a lack of consensus on the correct timing and use of these medications. This review seeks to provide a concise update of the available literature on the pathophysiology of CRSwNP, the evolution and cost utility of biologics as it pertains to management of patients with CRSwNP, and evidence for each available biologic and its use in CRSwNP.